

GI CANCER INSIGHTS

2ND NOVEMBER 2026

"NEW STANDARDS, NEW STRATEGIES"

EDIFÍCIO EGAS MONIZ • AUDITÓRIO 58
FACULDADE DE MEDICINA DE LISBOA

CHAIRMEN

LUIS COSTA

CATARINA ABREU

ANA LÚCIA COSTA

ORGANIZATION



SECRETARIAT



WWW.ERUDITUS.PT
SEC.CONGRESSOS@ERUDITUS.PT
214430901 - 918027877

INSCRIÇÃO GRATUITA
MAS OBRIGATÓRIA



SPONSORS



14H15

Welcome & Introduction

14H30

SESSION 1: IMMUNOTHERAPY AND NUTRITION IN GI CANCER

Moderators: André Mansinho, Ana Lúcia Costa

Overcoming resistance: What modulates response to Immunotherapy?

Bruno Silva-Santos (PT)

Nutrition in GI cancer: Does metabolism matter?

Paula Ravasco (PT)

15H30

SESSION 2: FROM MOLECULAR PROFILING TO PERSONALIZED TREATMENT

Moderators: António Quintela, Nuno Bonito, Gonalo Costa

Precision Oncology in Colorectal Cancer:

Translating biology into practice

Dirk Arnold (DE)

Targeting strategies in Cholangiocarcinoma

Teresa Macarulla (SP)

Esophagogastric Adenocarcinoma: what changed the outcomes?

Sylvie Lorenzen (DE)

17H00

COFFEE BREAK & NETWORKING

17H30

SESSION 3: ORGAN PRESERVATION STRATEGIES IN RECTAL CANCER

Moderator: Catarina Abreu

Best Total Neoadjuvant Therapy (TNT) strategy

Sara Lonardi (IT)

Rectal cancer Watch and Wait strategies:

Patient Selection and Outcomes

Daniel Jordão (PT)

Round Table with the participation of:

Inês Leite (PT), Pedro Marques da Costa (PT);

Virgínia Mareco (PT), Catarina Abreu (PT)

18H30

CLOSING REMARKS

Bruno Silva-Santos (Portugal)

Bruno Silva-Santos is a Full Professor and Director of Immuno-Oncology at the Faculty of Medicine of the University of Lisbon, and Group Leader and Vice-Director of the Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. He got his PhD in Immunology from University College London in 2002 for work developed at Cancer Research UK (The London Research Institute), and then trained as a post-doc at King's College London, before establishing his own group at iMM in 2006. His research, which has been funded, among others, by the European Research Council (ERC) and the la Caixa Foundation, is mostly dedicated to gamma-delta T cells, having dissected novel molecular mechanisms of their differentiation and tumor cell recognition, published in over 100 papers in top international peer-reviewed journals. In 2019, Bruno Silva-Santos was elected Member of European Molecular Organization (EMBO) in recognition of his scientific contributions. His translational work on Immuno-Oncology was further recognized with awards from Pfizer, AstraZeneca, Janssen and Bial; and the nomination as Honorary Member of the European Academy of Tumor Immunology.

Paula Ravasco (Portugal)

Medical Doctor, Specialist in Immuno-haematology and Haemotherapy Nutritionist, Expert in Clinical Nutrition PhD with the Thesis: "Cancer: metabolic dysfunction, nutrition and Quality of Life" Principal Investigator and Team Leader Professor of Medicine, Nutrition and Scientific Research International postgraduate studies in clinical nutrition, research methodologies, data analysis and postgraduate studies in immunity, nutrition and health Member of ESPEN Faculty Coordinator of scientific and educational programs for international congresses, conferences and pre- and post-graduate courses, as well as preparation of guidelines in nutrition and medicine. Integrates the panel of teachers of advanced training courses in clinical nutrition and nutrition and cancer in collaboration with 2 European universities. Coordinator of the international advanced training program in Nutrition, Metabolism and Cancer Develops clinical activity and research in the area of nutrition, clinical nutrition, metabolism, oncology, Quality of Life and outcomes, disease/treatment modulation Lead researcher in collaborative projects at national and international level with various health institutions, higher education institutions and research laboratories.

Dirk Arnold (Germany)

Dirk Arnold is Director of the Asklepios Tumorzentrum Hamburg, a network cancer centre serving 7 community hospitals in Hamburg, and also Head of the department of Oncology, Haematology and Palliative Care at AK Altona, Hamburg. Before taking this position, he was 2010 appointed as Director of the University Cancer Centre in Hamburg (UCCH) and held positions at the University Departments for Oncology and Haematology in Halle-Wittenberg, Freiburg and Berlin. Between 2015 and 2017, he served as Director of the Instituto CUF de Oncologia in Lisbon, Portugal.

His major field of scientific interest are gastrointestinal cancers, and here specifically modern therapeutic approaches in biomarker-driven decision processes, and multimodal treatment strategies, also including other specialities. Here, he has served as chairman of Colorectal Cancer Study Group of the German AIO, a major collaborative group in clinical oncology. Within the AIO framework, he served as founding member of the Central Clinical Trials Office, underlining his expertise also in methodology of clinical research. Furthermore, his interest is the organisation of larger collaborative research structures and of integrated cancer centre networks.

Prof. Arnold is also member of the American Society of Clinical Oncology and Task Force Member of the National Cancer Institute, as well as Board member of the EORTC GI study group.

Within ESMO, he is a member of the ESMO-Magnitude of Clinical Benefit Scale Working Group (since 2023), Associate Editor for Annals of Oncology (since 2021), and member of the ESMO Open Editorial Board (since 2018). He is also an Ex-Officio Member of the ESMO Council and Chair of the ESMO Compliance and Ethics Committee (since 2021).

Teresa Macarulla (Spain)

Teresa Macarulla received her medical degree from the Universitat Autònoma de Barcelona, Spain. Afterwards, she completed her specialist training in medical oncology in Barcelona.

Dr. Macarulla is currently Head of the Medical Oncology Department at Hospital Clínic in Barcelona, Spain. She is working in Gastrointestinal Tumors Team and is involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies and related translational research, with a special focus on EGFR inhibitors, and also in phase II and III studies with new chemotherapy agents in gastrointestinal tumors, with special interest in hepatobiliopancreatic and colonic tumours.

Dra. Macarulla is the authors of numerous publications, many focusing on hepatobiliopancreatic and colonic tumors and new drugs, and authored communications at different conferences. She actively participates in the development of national and international clinical investigations, especially in relation to drugs directed against molecular targets, as well as clinical investigations for new chemotherapy agents. Dra. Macarulla is also an ad hoc reviewer for various oncology journals.

In addition, Dra Macarulla is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO).

Sylvie Lorenzen (Germany)

Prof Lorenzen is a consultant at the Department of Hematology and Oncology and Head of the Early Clinical Trial Unit, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.

Her clinical research interests include medical oncology, response evaluation in solid tumour therapy, multimodality treatment of gastrointestinal cancer and Phase I clinical trials. She has served as Principal Investigator or Sub-Investigator of multiple studies in the field (investigator-initiated trials and industry-sponsored registration studies).

Prof Lorenzen is chair of the Gastric Cancer Task Force of the Arbeitsgemeinschaft Internistische Onkologie (AIO; German Cancer Society), and a member of the Educational Steering Committee of the European Society for Medical Oncology (ESMO) and the Bavarian Ethics Commission. She is also designated Investigator of the German Consortium for Translational Research (DKTK), the Spokesperson and Coordinator of the German Gastric- and Esophageal Cancer Guidelines (S3-Leitlinien), First-author of the German Onkopedia Guidelines, Coauthor of the ESMO Gastroesophageal Cancer Guidelines (in preparation) and speaker for the BZKF Gastroesophageal Working Group.

Prof Lorenzen is a scientific advisor/reviewer for a number of journals including *Annals of Oncology*, *Annals of Surgical Oncology*, *Oncology*, *European Journal of Nuclear Medicine and Expert Opinion on Emerging Drugs*. I am Review Editor for *Frontiers in Oncology* and has been Editor-in-Chief of the *Journal Oncology Research and Treatment* since 2020.

Sara Lonardi (Italy)

Sara Lonardi is Chief of the Oncology 3 Unit of Veneto Institute of Oncology (IOV) – IRCCS.

She obtained her Medical Degree in 2000 and her Oncology specialization in 2004, both from the University of Padova.

She is actively interested in the care of gastrointestinal cancer patients since 1998, and in 2013 became chief of the GI Cancer Unit, being involved in several international and national clinical trials as Principal Investigator. She was also Chief of Phase I Clinical Trial Unit at IOV-IRCCS.

She has published more than two hundred scientific articles in peer-reviewed journal dealing with gastrointestinal cancers clinical and translational research.

She is active member of Associazione Italiana di Oncologia Medica-AIOM, European Society of Medical Oncology-ESMO and American Society of Medical Oncology-ASCO, and member of the Steering Committee of the ACCENT DataBase.

Daniel Jordão (Portugal)

He obtained his Integrated Master's Degree in Medicine from the Faculty of Medicine of the University of Lisbon in 2012. Following his General Training at CHULN, he completed his specialist training in General Surgery at the Portuguese Institute of Oncology in Coimbra, with a particular focus on soft tissue sarcomas. In 2017, he completed a Sarcoma Fellowship at the Istituto Nazionale dei Tumori in Milan and contributed to the multidisciplinary sarcoma team at IPO Coimbra, where he was responsible for revising the institutional protocol for sarcoma diagnosis and treatment. He obtained a Master's Degree in Musculoskeletal Tumors from Universidad Europea de Madrid in 2019. In 2020, he became a Consultant in General Surgery and joined the sarcoma and gastrointestinal multidisciplinary teams, becoming responsible for GISTs within the General Surgery Department at IPO Coimbra. Since 2021, he has been a Fellow of the European Board of Surgical Oncology. Since 2022, he has been a Consultant in General Surgery at CHULN, where he is a member of the colorectal surgery team and leads the sarcoma program. He is also responsible for the training of surgical residents and has been an Invited Assistant Professor of Surgery II at the Faculty of Medicine of the University of Lisbon since 2022.